MMWR Morb Mortal Wkly Rep. 2001 Apr 20;50(15):289-91.
One of the recommended treatments for latent tuberculosis infection (LTBI) is a 9-month regimen of isoniazid (INH); a 2-month regimen of rifampin (RIF) and pyrazinamide (PZA) is an alternative in some instances. In September 2000, a man in New York died of hepatitis after 5 weeks of RIF-PZA, and in December, a woman in Georgia was admitted to a hospital because of hepatitis after 7 weeks of this regimen. This report summarizes the findings of the investigations of these incidents, which underscore the need for clinical monitoring for adverse effects in all patients receiving treatment for LTBI.
潜伏性结核感染（LTBI）的推荐治疗方法之一是采用异烟肼（INH）进行为期9个月的治疗方案；在某些情况下，可选择使用利福平（RIF）和吡嗪酰胺（PZA）进行为期2个月的治疗方案。2000年9月，纽约一名男子在接受利福平-吡嗪酰胺治疗5周后死于肝炎，12月，佐治亚州一名女子在接受该治疗方案7周后因肝炎住院。本报告总结了对这些事件的调查结果，强调了对所有接受LTBI治疗的患者进行不良反应临床监测的必要性。
